337 related articles for article (PubMed ID: 18304744)
21. Uptake of inorganic mercury in the olfactory bulbs via olfactory pathways in rats.
Henriksson J; Tjälve H
Environ Res; 1998 May; 77(2):130-40. PubMed ID: 9600806
[TBL] [Abstract][Full Text] [Related]
22. Olfactory targeting through intranasal delivery of biopharmaceutical drugs to the brain: current development.
Wen MM
Discov Med; 2011 Jun; 11(61):497-503. PubMed ID: 21712015
[TBL] [Abstract][Full Text] [Related]
23. Genomic effects of once-weekly, intramuscular interferon-beta1a treatment after the first dose and on chronic dosing: Relationships to 5-year clinical outcomes in multiple sclerosis patients.
Weinstock-Guttman B; Bhasi K; Badgett D; Tamaño-Blanco M; Minhas M; Feichter J; Patrick K; Munschauer F; Bakshi R; Ramanathan M
J Neuroimmunol; 2008 Dec; 205(1-2):113-25. PubMed ID: 18950872
[TBL] [Abstract][Full Text] [Related]
24. Intranasal drug targeting of hypocretin-1 (orexin-A) to the central nervous system.
Dhuria SV; Hanson LR; Frey WH
J Pharm Sci; 2009 Jul; 98(7):2501-15. PubMed ID: 19025760
[TBL] [Abstract][Full Text] [Related]
25. Time-dependent translocation and potential impairment on central nervous system by intranasally instilled TiO(2) nanoparticles.
Wang J; Liu Y; Jiao F; Lao F; Li W; Gu Y; Li Y; Ge C; Zhou G; Li B; Zhao Y; Chai Z; Chen C
Toxicology; 2008 Dec; 254(1-2):82-90. PubMed ID: 18929619
[TBL] [Abstract][Full Text] [Related]
26. Interferon-beta bioactivity measurement in multiple sclerosis: feasibility for routine clinical practice.
van der Voort LF; Kok A; Visser A; Oudejans CB; Caldano M; Gilli F; Bertolotto A; Polman CH; Killestein J
Mult Scler; 2009 Feb; 15(2):212-8. PubMed ID: 18805837
[TBL] [Abstract][Full Text] [Related]
27. Insights into direct nose to brain delivery: current status and future perspective.
Mittal D; Ali A; Md S; Baboota S; Sahni JK; Ali J
Drug Deliv; 2014 Mar; 21(2):75-86. PubMed ID: 24102636
[TBL] [Abstract][Full Text] [Related]
28. Distribution of the non-AT1, non-AT2 angiotensin-binding site in the rat brain: preliminary characterization.
Karamyan VT; Speth RC
Neuroendocrinology; 2008; 88(4):256-65. PubMed ID: 18562784
[TBL] [Abstract][Full Text] [Related]
29. The olfactory nerve and not the trigeminal nerve is the major site of CNS entry for mouse hepatitis virus, strain JHM.
Barnett EM; Perlman S
Virology; 1993 May; 194(1):185-91. PubMed ID: 8386871
[TBL] [Abstract][Full Text] [Related]
30. Long-term follow-up of the original interferon-beta1b trial in multiple sclerosis: design and lessons from a 16-year observational study.
Ebers GC; Reder AT; Traboulsee A; Li D; Langdon D; Goodin DS; Wolf C; Beckmann K; Konieczny A;
Clin Ther; 2009 Aug; 31(8):1724-36. PubMed ID: 19808131
[TBL] [Abstract][Full Text] [Related]
31. Drug brain distribution following intranasal administration of Huperzine A in situ gel in rats.
Zhao Y; Yue P; Tao T; Chen QH
Acta Pharmacol Sin; 2007 Feb; 28(2):273-8. PubMed ID: 17241531
[TBL] [Abstract][Full Text] [Related]
32. Intranasal delivery of ESBA105, a TNF-alpha-inhibitory scFv antibody fragment to the brain.
Furrer E; Hulmann V; Urech DM
J Neuroimmunol; 2009 Oct; 215(1-2):65-72. PubMed ID: 19733918
[TBL] [Abstract][Full Text] [Related]
33. Rapid transport within cerebral perivascular spaces underlies widespread tracer distribution in the brain after intranasal administration.
Lochhead JJ; Wolak DJ; Pizzo ME; Thorne RG
J Cereb Blood Flow Metab; 2015 Mar; 35(3):371-81. PubMed ID: 25492117
[TBL] [Abstract][Full Text] [Related]
34. Interferon-beta: mechanism of action and dosing issues.
Markowitz CE
Neurology; 2007 Jun; 68(24 Suppl 4):S8-11. PubMed ID: 17562848
[TBL] [Abstract][Full Text] [Related]
35. [Comparison of the distribution of breviscapine in the brain by different administration routes].
Shi SL; Xu LY; Wu JJ; Li CY; Ge WH; Dai WY
Yao Xue Xue Bao; 2009 May; 44(5):515-8. PubMed ID: 19618729
[TBL] [Abstract][Full Text] [Related]
36. Olfactory toxicity resulting from dermal application of 2,6-dichlorobenzonitrile (dichlobenil) in the C57Bl mouse.
Deamer NJ; O'Callaghan JP; Genter MB
Neurotoxicology; 1994; 15(2):287-93. PubMed ID: 7991217
[TBL] [Abstract][Full Text] [Related]
37. Therapy with interferon-beta modulates endogenous catecholamines in lymphocytes of patients with multiple sclerosis.
Zaffaroni M; Marino F; Bombelli R; Rasini E; Monti M; Ferrari M; Ghezzi A; Comi G; Lecchini S; Cosentino M
Exp Neurol; 2008 Dec; 214(2):315-21. PubMed ID: 18824168
[TBL] [Abstract][Full Text] [Related]
38. Effect of physicochemical properties on intranasal nanoparticle transit into murine olfactory epithelium.
Mistry A; Glud SZ; Kjems J; Randel J; Howard KA; Stolnik S; Illum L
J Drug Target; 2009 Aug; 17(7):543-52. PubMed ID: 19530905
[TBL] [Abstract][Full Text] [Related]
39. Type I interferon response in the central nervous system.
Paul S; Ricour C; Sommereyns C; Sorgeloos F; Michiels T
Biochimie; 2007; 89(6-7):770-8. PubMed ID: 17408841
[TBL] [Abstract][Full Text] [Related]
40. Interferon-gamma-like immunoreactivity in certain neurons of the central and peripheral nervous system.
Ljungdahl A; Olsson T; Van der Meide PH; Holmdahl R; Klareskog L; Höjeberg B
J Neurosci Res; 1989 Nov; 24(3):451-6. PubMed ID: 2512393
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
